ストックスクリーナーアプリを入手
30.56
11.03%
3.17
前日終値:
$27.39
開ける：
$27.55
24時間の取引高:
13.46M
Relative Volume:
0.82
時価総額：
$7.12B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
58.53
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+1.47%
1か月 パフォーマンス:
-7.40%
6か月 パフォーマンス:
+92.23%
1年 パフォーマンス:
-27.90%
1日の値動き範囲:
$27.41
$30.71
1週間の範囲:
$27.38
$30.71
52週間の値動き範囲:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
30.50 | 6.39B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.39 | 57.64B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.44 | 42.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.8809 | 42.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.22 | 30.56B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.63 | 22.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.8%What's Next? - MarketBeat
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access - Benzinga
Hims & Hers Health sees 17x international reven... - Pluang
Wellness Briefing: Hims & Hers plots rapid expansion into peptide therapies like BPC-157, plus news - glossy.co
Hims & Hers: Buying The Margin Dip (NYSE:HIMS) - Seeking Alpha
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) - marketscreener.com
Hims & Hers' Chief Accounting Officer Is Leaving. Here's What Her Latest Insider Filing Shows - The Motley Fool
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip - The Motley Fool
A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know - The Motley Fool
An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know - The Motley Fool
The CTO of Hims & Hers Just Gave Up Nearly $2.7 Million in Stock. Here's What It Actually Means - The Motley Fool
What Long-Term Investors Should Know About This Hims Insider Filing - The Motley Fool
Hims & Hers' CEO Just Disposed of 78,859 Shares. Here's What Long-Term Investors Should Know. - The Motley Fool
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip - The Motley Fool
Hims & Hers' Policy Chief Just Filed an Insider Transaction. Here's What It Means. - The Motley Fool
Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO - Business Insider
Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss - wsj.com
Hims & Hers faces FTC lawsuit over privacy brea... - Pluang
Is Hims & Hers Health Inc (HIMS) a Bargain After 4.3% Drop? GF V - GuruFocus
Why Is Hims & Hers Health (HIMS) Facing A New Privacy Lawsuit? - Yahoo Finance
Oluyemi Okupe Sells 55,383 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $261,831.32 in Stock - MarketBeat
Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following - GlobeNewswire
Hims & Hers CEO Andrew Dudum Says AI Health Coach Could Be Just 12 Months Away, Believes It Could Increase Medication Adherence - Stocktwits
Kaplan Fox Announces an Investigation Into Hims & Hers Health, In - The National Law Review
Hims & Hers Health Options Spot-On: On August 18th, 65,547 Contracts Were Traded, With 886.89K Open Interest - moomoo.com
HIMS Looks 34.0% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Hims CEO responds to FTC suit, sees GLP-1 prices falling to $40-$50: CNBC - Seeking Alpha
Hims & Hers CEO Andrew Dudum pushes back on FTC lawsuit - qz.com
Hims & Hers CEO pushes back against FTC suit, says "we are active disruptors" - Investing.com Nigeria
Hims & Hers CEO Tells the FTC That Regulators Just Don’t Understand - Yahoo Finance
Hims & Hers CEO says FTC lawsuit misunderstands how the company works - CNBC
Hims & Hers: Eucalyptus Deal Unlocks New Markets (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Stock Short Interest Rises to 32.05% - Quiver Quantitative
HIMS Stock Has Quadrupled In 5 Years: How Hims Turned A $3 Stock Into A Telehealth Giant - Stocktwits
Hims & Hers Stock (HIMS) Opinions on Five-Year Public Listing Anniversary - Quiver Quantitative
Financial Markets Wall Street - Dayton Daily News
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Possible Securities Law Violations - The National Law Review
HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - Stocktwits
5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call - Yahoo Finance
HIMS Stock Climbs Overnight: Oscar Health CEO Courts Hims For New Drug Marketplace - Stocktwits
Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks - Stocktwits
Hims & Hers Health (NYSE:HIMS) Upgraded to Hold at Wall Street Zen - MarketBeat
Hims & Hers Health, Inc. • Robinhood Token Price, HIMS Price, Live Charts, and Marketcap - Coinbase
Hims & Hers Health CTO Mohamed Elshenawy Awarded 1.2 Million RSUs - Kalkine Media
Hims & Hers Health Director Christopher D. Payne Awarded 8,768 RSUs in August 2026 - Kalkine Media
Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset? - Yahoo Finance
Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop - pluang.com
Hims & Hers Health's Next Act: Making Its Own Drugs Again (NYSE:HIMS) - Seeking Alpha
Investor relations - HIMS investor relations
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
2.59%
大文字化:
|
ボリューム (24 時間):